News | October 14, 2013

Boston Scientific Begins Clinical Trial Of Innova Peripheral Vascular Drug-Eluting Stent

boston scientific stents peripheral clinical trial study innova des drug-eluting

October 14, 2013 — Launching a clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corp. Innova Drug-Eluting Stent (DES) System.

The Majestic trial, designed to evaluate the safety and performance of the first Boston Scientific peripheral drug-eluting stent system, is projected to enroll 55 patients across 15 centers in Europe, Australia and New Zealand.

The Innova DES System is designed to restore blood flow in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The stent features a drug-polymer combination, intended to facilitate optimal release of the drug and prevent restenosis of the vessel. The first implant was performed by Andrew Holden, M.D., and director of interventional radiology, Auckland City Hospital, Auckland, New Zealand.

The Innova DES System consists of a paclitaxel-coated, nitinol, self-expanding stent loaded on a low-profile delivery system. The innovative stent architecture features a closed-cell design at each end of the stent for more consistent deployment, and an open-cell design along the stent body for improved flexibility and fracture resistance. A tri-axial catheter shaft designed to provide added support facilitates deployment accuracy.

The Innova DES System is an investigational device and is not available for use or sale.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init